Search
Eterna Therapeutics Inc
ERNAAdd to Watchlist
6.270USD
-0.300-4.46%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
49.24MMarket Cap
LossP/E TTM
More Details of Eterna Therapeutics Inc Company
Ernexa Therapeutics Inc., formerly Eterna Therapeutics Inc., is a preclinical-stage company. The Company is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The Company seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The Company is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Eterna Therapeutics Inc Info
Ticker SymbolERNA
Company nameErnexa Therapeutics Inc
IPO dateAug 29, 1991
CEOLuther (Sanjeev)
Number of employees6
Security typeOrdinary Share
Fiscal year-endAug 29
Address1035 Cambridge Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02141
Phone16177986700
Websitehttps://www.ernexatx.com/
Ticker SymbolERNA
IPO dateAug 29, 1991
CEOLuther (Sanjeev)
Company Executives of Eterna Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
-100.00%
Name
Name/Position
Position
Shareholding
Change
Ms. Sandra Gurrola
Ms. Sandra Gurrola
Senior Vice President - Finance
Senior Vice President - Finance
--
--
Mr. William Wexler
Mr. William Wexler
Independent Director
Independent Director
--
--
Dr. James Bristol
Dr. James Bristol
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Sanjeev Luther
Mr. Sanjeev Luther
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Mr. Peter Cicala
Mr. Peter Cicala
Independent Director
Independent Director
--
--
Dr. Elena Ratner
Dr. Elena Ratner
Independent Director
Independent Director
--
-100.00%
FAQs
Who are the top five shareholders of Eterna Therapeutics Inc?
The top five shareholders of Eterna Therapeutics Inc are: Ms. Sandra Gurrola
How many institutions hold shares of Eterna Therapeutics Inc (ERNA)?
As of 2026Q1, 44 institutions hold shares of Eterna Therapeutics Inc, with a combined market value of approximately 23.70K, accounting for 2.03% of the total shares. Compared to 2025Q4, institutional shareholding has increased by 749.00.
What is the biggest source of revenue for Eterna Therapeutics Inc?
In 2026Q1, the Subscription revenue business generated the highest revenue for Eterna Therapeutics Inc, amounting to 4.88M and accounting for 84.17% of total revenue.